CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas
Authors:
Open Access
- 13 October 2023
- journal article
- letter
- Published by Springer Nature in Acta Neuropathologica
- Vol. 146 (6) , 845-847
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaNew England Journal of Medicine, 2023
- Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomasNeuro-Oncology, 2023
- CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomasNeuro-Oncology, 2019
- Novel, improved grading system(s) for IDH-mutant astrocytic gliomasActa Neuropathologica, 2018
- OncoKB: A Precision Oncology Knowledge BaseJCO Precision Oncology, 2017
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencingNucleic Acids Research, 2016
- CDKN2ALoss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) AstrocytomasJournal of Neuropathology & Experimental Neurology, 2015
- Continuous growth of mean tumor diameter in a subset of grade II gliomasAnnals of Neurology, 2003
- Detection of p 16, RB, CDK4, and p53 Gene Deletion and Amplification by Fluorescence In Situ Hybridization in 96 GliomasAmerican Journal of Clinical Pathology, 1999